A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors

Ítems similars

• Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
  per: Kelly, Ronan J, et al.
  Publicat: (2015)
• Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
  per: Rizvi, Naiyer, et al.
  Publicat: (2015)
• Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
  per: Yang, Hui, et al.
  Publicat: (2018)
• Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
  per: Gilbert, Jill, et al.
  Publicat: (2015)
• Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
  per: Rizvi, Naiyer, et al.
  Publicat: (2015)